BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01, which is developed for the treatment of drug resistant
focal epilepsy.
Read the full interview with Martin Linhult at biostock.se:
https://www.biostock.se/en/interview-with-combigenes-new-cmc-expert/